WiCON and major US investment firms seek M&A opportunities in the Chinese Pharma Industry
WiCON International Group has recently reached agreement with a number of major US investment firms to help them identify, screen and negotiate with potential M&A opportunities in the Chinese pharmaceutical industry.
Ideal candidates should be profitable, have at least an annual sales of RMB 200 million, and need equity investment at and above US$20 million.
Interested party please contact us at (010) 62354966 ext. 801 or e-mail: email@example.com.